Matches in Wikidata for { <http://www.wikidata.org/entity/Q97563200> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q97563200 description "2020 թվականի հուլիսի 11-ին հրատարակված գիտական հոդված" @default.
- Q97563200 description "artículu científicu espublizáu en xunetu de 2020" @default.
- Q97563200 description "im Juli 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q97563200 description "scientific article published on 11 July 2020" @default.
- Q97563200 description "wetenschappelijk artikel" @default.
- Q97563200 description "наукова стаття, опублікована 11 липня 2020" @default.
- Q97563200 name "A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation" @default.
- Q97563200 name "A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation" @default.
- Q97563200 type Item @default.
- Q97563200 label "A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation" @default.
- Q97563200 label "A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation" @default.
- Q97563200 prefLabel "A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation" @default.
- Q97563200 prefLabel "A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation" @default.
- Q97563200 P1433 Q97563200-56548ABA-172D-4A54-80DD-43564B6C8EEF @default.
- Q97563200 P1476 Q97563200-E439052B-A2C2-4F40-B2A5-8C7DBB79381C @default.
- Q97563200 P2093 Q97563200-29191CD5-F38A-471C-8944-D113FA2ECD08 @default.
- Q97563200 P2093 Q97563200-2E6A537F-EC1C-40F9-9FC5-E3993651CAD3 @default.
- Q97563200 P2093 Q97563200-3FFB8530-FFDD-4DEA-92CE-08482445FB58 @default.
- Q97563200 P2093 Q97563200-55D64DF2-A0A8-44C7-A3E3-FCE7891041E5 @default.
- Q97563200 P2093 Q97563200-56D44CBF-43B0-488C-B9E3-5B244BE7C3BE @default.
- Q97563200 P2093 Q97563200-79DADFB4-BC2E-4E0E-A9ED-52DFB3D12620 @default.
- Q97563200 P2093 Q97563200-9D9B3876-75C0-45A0-8565-6F359247948C @default.
- Q97563200 P2093 Q97563200-A7F628FD-99E0-4D99-8B20-30A52CA46650 @default.
- Q97563200 P2093 Q97563200-AA680191-593E-48C2-BE40-F55457C94C4E @default.
- Q97563200 P2093 Q97563200-ABB0BBBC-5C40-4911-9FFB-17C65DEE09D5 @default.
- Q97563200 P2093 Q97563200-B7362ABD-AE3D-43D6-AE87-DEE0965EA005 @default.
- Q97563200 P2093 Q97563200-D39D0228-2A79-46A3-8662-9892357B3196 @default.
- Q97563200 P2093 Q97563200-D79947EC-6193-46CD-B12A-200B1C8BCB82 @default.
- Q97563200 P275 Q97563200-61c92c41-45a9-40b3-99e1-327aa28bdcea @default.
- Q97563200 P31 Q97563200-5633D305-3785-400E-8F80-475B944AFAFC @default.
- Q97563200 P356 Q97563200-E32C25B8-E9A3-4919-BB91-1D1E9BEB453C @default.
- Q97563200 P433 Q97563200-F4C942A2-497D-40FB-86AD-F275724AABFB @default.
- Q97563200 P478 Q97563200-64EE1604-B35D-4170-8E25-16D52192435C @default.
- Q97563200 P577 Q97563200-B35D10D0-3A48-4537-BD57-F807BA6DE143 @default.
- Q97563200 P6216 Q97563200-b36393d4-b9c1-448a-94b1-c9e76c07f488 @default.
- Q97563200 P698 Q97563200-54AE5420-16FF-4344-ADBF-8FBEEC2FE6CA @default.
- Q97563200 P921 Q97563200-E49BAEA8-561E-46EE-AC26-4D888C38423B @default.
- Q97563200 P356 VACCINES8030377 @default.
- Q97563200 P698 32664486 @default.
- Q97563200 P1433 Q27725508 @default.
- Q97563200 P1476 "A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation" @default.
- Q97563200 P2093 "B Hill" @default.
- Q97563200 P2093 "B Somerville" @default.
- Q97563200 P2093 "C S Schmaljohn" @default.
- Q97563200 P2093 "D Hannaman" @default.
- Q97563200 P2093 "Jay Hooper" @default.
- Q97563200 P2093 "K M Paolino" @default.
- Q97563200 P2093 "K Mills" @default.
- Q97563200 P2093 "M Cohen" @default.
- Q97563200 P2093 "M Josleyn" @default.
- Q97563200 P2093 "M Sanchez-Lockhart" @default.
- Q97563200 P2093 "M Wisniewski" @default.
- Q97563200 P2093 "S Kwilas" @default.
- Q97563200 P2093 "S Norris" @default.
- Q97563200 P275 Q20007257 @default.
- Q97563200 P31 Q13442814 @default.
- Q97563200 P356 "10.3390/VACCINES8030377" @default.
- Q97563200 P433 "3" @default.
- Q97563200 P478 "8" @default.
- Q97563200 P577 "2020-07-11T00:00:00Z" @default.
- Q97563200 P6216 Q50423863 @default.
- Q97563200 P698 "32664486" @default.
- Q97563200 P921 Q9002005 @default.